TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23579344
Drug: Fixed-combination brinzolamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-combination brinzolamide, 1%, and brimonidine, 0.2%
Study: 20522466
Drug: Peer-mentoring by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer-mentoring by a lay-worker fortnightly during pregnancy and monthly for the following year, tailored to participants' wishes (home visits/telephone contacts), additional to usual care.
Study: 9160916
Drug: Cimetidine (local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (local treatment for 4 weeks)
Study: 8105773
Drug: Brimonidine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine administered before the procedure
Study: 8105773
Drug: Brimonidine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine administered after the procedure
Study: 8105773
Drug: Vehicle administered
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle administered before and after the procedure
Study: 26774112
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (80 mL and 30 mL)
Study: 14636909
Drug: Cilostazol 100
Normalized name: cilostazol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol 100 mg twice daily for 6 weeks
Study: 8623945
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 20 mL of propofol alone in a commercial preparation (Diprivan(R) with 10 mL of saline)
Study: 8623945
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: 20 mL of propofol and 10 mL of LCT fat emulsion
Study: 8623945
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 20 mL of propofol with 5 mL of long‐chain triglyceride (LCT) fat emulsion and 5 mL of saline
Study: 23106878
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate (TU) capsules, 120 - 160 mg daily for 6 months
Study: 23106878
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate (TU) capsules
Study: 18626271
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (1.0 mg/kg) MDMA
Study: 10220130
Drug: New antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: New antipsychotics
Study: 31554388
Drug: 14-day high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day high dose PPI-bismuth-containing quadruple therapy with probiotics (37.5 mg Lactobacillus reuteri, Biogaia® in tablet twice daily)
Study: 31554388
Drug: 7-day high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day high dose PPI-bismuth-containing quadruple therapy with probiotics
Study: 31554388
Drug: 14-day high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day high dose PPI-bismuth-containing quadruple therapy with probiotics
Study: 27858873
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + Dexrazoxane (Chemo + DRZ)
Study: 27858873
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (Chemo)
Study: 20507398
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg every other week (eow)
Study: 17365264
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg weekly
Study: 20298496
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (adalimumab eow, adalimumab weekly, placebo)
Study: 18205098
Drug: Aliskiren and
Normalized name: aliskiren and amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren and Ramipril combination
Study: 2844981
Drug: Deferred maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred maintenance therapy after crossover
Study: 31590179
Drug: Naltrexone (NTX;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (NTX; 50 mg/day) + placebo memantine
Study: 31590179
Drug: Naltrexone (NTX;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (NTX; 50 mg/day) alone
Study: 25440636
Drug: Respiratory rate
Normalized name: respiratory rate measuring device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory rate of 15 cycles/min with low-tidal-volume (5 mL/kg) and two-lung ventilation
Study: 25440636
Drug: Respiratory rate
Normalized name: respiratory rate measuring device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory rate of 18 cycles/min with low-tidal-volume (5 mL/kg) and two-lung ventilation
Study: 25440636
Drug: Respiratory rate
Normalized name: respiratory rate measuring device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory rate of 22 cycles/min with low-tidal-volume (5 mL/kg) and two-lung ventilation
Study: 24377221
Drug: Intermittent wave
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent wave (IW) electroacupuncture combined with rehabilitation therapy
Study: 24377221
Drug: Disperse-dense wave
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disperse-dense wave (DW) electroacupuncture combined with rehabilitation therapy
Study: 24377221
Drug: Continuous wave
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous wave (CW) electroacupuncture combined with rehabilitation therapy
Study: 19012954
Drug: MRKAd5 HIV-1
Normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRKAd5 HIV-1 gag/pol/nef vaccine
Study: 7422170
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of ethinyl estradiol and levonorgestrel (Nordiol)
Study: 30565715
Drug: CHx/alcohol‐combination (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHx/alcohol‐combination (1% CHx and 61% ethanol) applied with rub technique
Study: 20297707
Drug: Conventional Restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Restorative Treatment (CRT)
Study: 27029801
Drug: Atraumatic Restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic Restorative Treatment (ART)
Study: 21524172
Drug: Ultra-Conservative Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-Conservative Treatment (UCT)
Study: 10753002
Drug: Metrifonate 60/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate 60/80 mg
Study: 7863722
Drug: Chewable pyrantel
Normalized name: pyrantel Chewable Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewable pyrantel pamoate tablets (pulverized)
Study: 2644954
Drug: Surgery and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery and Radiation Therapy
Study: 235144
Drug: Weekly psychotherapy
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly psychotherapy
Study: 235144
Drug: Once monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once monthly psychotherapy
Study: 10678268
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg prazosin
Study: 21693504
Drug: Reduction in
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction in systolic blood pressure (SBP) during treatment
Study: 18274852
Drug: Finalized questionnaire
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finalized questionnaire administered to patients
Study: 15580194
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment (1mg/m2/day)
Study: 8273900
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia (IVPCA) with 10 mg pethidine
Study: 8273900
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia (IVPCA) with 20 mg pethidine
Study: 29294081
Drug: Daily Activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Activities control condition
Study: 18261537
Drug: Enalapril (E)
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril (E) 10 mg/d
Study: 18261537
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (E(−):L(−))
Study: 14608128
Drug: Bivalirudin high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin high-dose group (1 mg/kg bolus; 2.5 mg/kg/hour infusion for 4 hours)
Study: 14608128
Drug: Bivalirudin low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bivalirudin low-dose group (0.75 mg/kg bolus; 1.75 mg/kg/hour infusion)
Study: 14608128
Drug: Bivalirudin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin (both high and low dose)
Study: 8462363
Drug: High-dose octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose octreotide (N = 9)
Study: 21678169
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of implementation intentions and self-efficacy (II + SE)
Study: 9666765
Drug: Single-dose antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose antibiotic prophylaxis with 1 g of ceftriaxone intravenously 1-2 hours before surgery
Study: 7634503
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose r‐hGH (20 IU/m2/week)
Study: 7634503
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose r‐hGH (40 IU/m2/week)
Study: 7634503
Drug: r‐hGH therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐hGH therapy
Study: 10895994
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (PT)
Study: 25791116
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated recombinant tetravalent dengue vaccine candidate (TDV), given in 2 doses 90 days apart
Study: 20971463
Drug: Conventional intracytoplasmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intracytoplasmic sperm injection (ICSI); n = 53 couples
Study: 7674688
Drug: No anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anticoagulation or antiplatelet therapy
Study: 22157392
Drug: Azithromycin ophthalmic
Normalized name: azithromycin ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin ophthalmic solution 1% administered bid on days 1 and 2 and on days 3 to 29±1
Study: 22157392
Drug: Visine for
Normalized name: Visine for Contacts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visine for Contacts rewetting drops administered qid on days 1 to 29±1
Study: 20813346
Drug: Azithromycin ophthalmic
Normalized name: azithromycin ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin ophthalmic solution 1%
Study: 11175372
Drug: Intrathecal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal administration of 4-aminopyridine at 5 microg/h for 4-5 hours
Study: 3995960
Drug: Cervical priming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical priming with sulprostone gel
Study: 28602825
Drug: Bone Level
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone Level Implants (OsseoSpeed TX, Astra tech)
Study: 28602825
Drug: Tissue Level
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue Level Implants (RN SLActive®, Straumann)
Study: 9506336
Drug: Aspirin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (250 mg/day)
Study: 10697373
Drug: Tiklid (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiklid (500 mg/day) + Aspirin (250 mg/day)
Study: 8222740
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil (6 g/day)
Study: 8222740
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil and Fish oil preparation
Study: 3896432
Drug: Epidural morphine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine, 5 mg in 10 ml 0.9% NaCl
Study: 30412147
Drug: Add-back hormone
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Add-back hormone replacement therapy with mineral waters (MW) and radon therapy (RT) combined with triptorelin in the main group (MG)
Study: 30412147
Drug: Triptorelin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin treatment in the control group (CG)
Study: 15676038
Drug: Giona Easyhaler
Normalized name: GLYCERIN 0.045 g in 100 mL TOPICAL LIQUID [DIONA CELL REGENERATION BOOSTER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Giona Easyhaler 200 microg/dose
Study: 15676038
Drug: Pulmicort Turbuhaler
Normalized name: Pulmicort Turbuhaler
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pulmicort Turbuhaler 200 microg/dose
Study: 15676038
Drug: Charcoal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Charcoal administration (40 g)
Study: 27557833
Drug: Rolapitant 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rolapitant 180 mg
Study: 15149513
Drug: Lipid microspheres
Normalized name: perflutren lipid microspheres
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid microspheres loaded with 0.025% clobetasol propionate (formulation A)
Study: 15149513
Drug: Lipophilic ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipophilic ointment in a hydrophilic phase 0.025% (formulation B)
Study: 11052430
Drug: Protective mechanical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective mechanical ventilation (PV; respiratory rate, 16 breaths/min; tidal volume, 6 mL/kg; FIO2, 1.0; PEEP, +5)
Study: 11052430
Drug: Conventional mechanical
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional mechanical ventilation (CV; respiratory rate, 8 breaths/min; tidal volume, 12 mL/kg; FIO2, 1.0; PEEP, +5)
Study: 9771950
Drug: Doxorubicin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (30 mg) plus Verapamil (15 mg)
Study: 8155011
Drug: Lazabemide 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazabemide 100 mg/d
Study: 25526495
Drug: Artificial liver
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial liver support system (ALSS) plus standard medical therapy (SMT), n = 104
Study: 25526495
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (SMT) alone, n = 130
Study: 16563207
Drug: Self-reported medication
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported medication adherence
Study: 17242421
Drug: Self-reported medication
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported medication adherence <80%
Study: 2085577
Drug: Povidone iodine
Normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone iodine and nonocclusive dressings changed 2 to 3 times weekly
Study: 158569
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide gel 2.5%
Study: 1451291
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide gel 5%
Study: 158569
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide gel (both strengths)
Study: 30598384
Drug: Farmed Atlantic
Normalized name: Atlantic mackerel
DrugBank: Atlantic mackerel (DB15542)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Farmed Atlantic salmon consumption (3 times weekly for 16 weeks)
Study: 30598384
Drug: Meat consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meat consumption (3 times weekly for 16 weeks)
Study: 19322115
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol releasing 0.014 mg estradiol (E2)/week
Study: 15095035
Drug: Milk powder
Normalized name: Milk powder
DrugBank: Skim milk (DB15546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk powder equivalent to 1300 mg calcium
Study: 15095035
Drug: Milk powder
Normalized name: Milk powder
DrugBank: Skim milk (DB15546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk powder equivalent to 650 mg calcium
Study: 11822993
Drug: Oral cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cocaine 150 mg
Study: 11822993
Drug: Oral cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cocaine 200 mg
Study: 10078487
Drug: Control (meningococcal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (meningococcal vaccine, pneumococcal vaccine, or placebo)
Study: 2251976
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg BCH 069 (intravenous injection) 3 times weekly for 6 weeks
Study: 2251976
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg BCH 069 (subcutaneous injection) 3 times weekly for 4 weeks
Study: 28939607
Drug: Mupirocin-based decolonization
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin-based decolonization therapy
Study: 19335843
Drug: Newer agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer agents
Study: 17163096
Drug: Classic six
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classic six cycles of intravenous CMF
Study: 24812894
Drug: Comprehensive Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive Western therapy plus blood cooling and detoxification recipe (BCDR)
Study: 24812894
Drug: Comprehensive Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive Western therapy
Study: 22894746
Drug: Home self‐testing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home self‐testing for HIV using the OraQuick ADVANCE® HIV‐1/2 Antibody Test on oral fluids
Study: 12764859
Drug: Auto CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auto CPAP treatment in UPPP group
Study: 1875221
Drug: ABM infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ABM infusion after CVP
Study: 30893292
Drug: Everolimus with
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus with reduced-exposure calcineurin inhibitor (CNI, cyclosporine) followed by CNI withdrawal at weeks 7-11 post-transplant
Study: 16123484
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin (INH group)
Study: 1550700
Drug: Famotidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (40 mg orally)
Study: 3158146
Drug: Fentanyl 0.3
Normalized name: fentanyl 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.3 mg
Study: 29356761
Drug: Comparator (COMP:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator (COMP: intravenous ertapenem followed by oral amoxicillin/clavulanate)
Study: 21245996
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin plus rebamipide (Rebamipide group)
Study: 10853861
Drug: External nasal
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External nasal dilator strip (ENDS) with nasal decongestant
Study: 3128527
Drug: Cold air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold air inhalation (2 degrees C)
Study: 18612879
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg) for three days
Study: 15778874
Drug: Dronabinol (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol (10, 20 mg)
Study: 15778874
Drug: Dronabinol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol (30 mg)
Study: 15486365
Drug: Intensive oral
Normalized name: Uricalm Intensive Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive oral care (teeth and gingiva cleaned after every meal for 1 month)
Study: 15486365
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (performed their own oral care for 1 month)
Study: 9758291
Drug: Trovafloxacin 200
Normalized name: trovafloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trovafloxacin 200 mg once daily
Study: 9758291
Drug: Amoxicillin 1
Normalized name: amoxicillin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 1 g three times daily
Study: 356718
Drug: Theophylline and
Normalized name: theophylline and adrenergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline and hydroxyzine (basic combination)
Study: 21594560
Drug: D-cycloserine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine (100 mg)
Study: 31410659
Drug: Febuxostat therapy
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat therapy
Study: 31410659
Drug: No application
Approvals — FDA: no, EMA: no, PMDA: no
Description: No application of febuxostat therapy
Study: 10622051
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with doxycycline 100 mg twice daily for 10 days
Study: 2913892
Drug: Once-daily theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily theophylline preparation